Jonathan Hepple has joined the board of Mission Therapeutics Ltd as a non-executive director following the purchase by Rosetta Capital of a stake in Mission. Dr Hepple is co-founder and partner at Rosetta. Mission is developing drugs targeting the ubiquitin pathway for the treatment of kidney and neurodegenerative diseases and fibrosis. Dr Hepple is also a strategic advisor to Oxford Sciences Innovation. He holds a PhD in cancer research from the University of Cambridge and a bachelor’s degree in biology from the University of Oxford.
Mission Therapeutics announced the appointment on 24 March 2021.
Copyright 2021 Evernow Publishing Ltd